| Date | Title | Description |
| 13.06.2024 | Hepsor U34 SIA, Hepsor AS group company, signed 9 million euro loan agreement for financing the construction of StokOfiss 34 project in Riga | On June 12, 2024, Hepsor U34 SIA, Hepsor AS group company, and Latvian affiliate of Bigbank AS signed a loan agreement for the amount of 9 million euros. The purpose of the loan is to finance the construction of StokOfiss 34 development pro... |
| 11.12.2023 | Hepsor JG SIA, Hepsor AS group company, signed 4 million euro loan agreement for financing the construction of Annenhof Majas project | - |
| 24.04.2023 | Hepsor RD5 SIA, Hepsor AS group company, signed 4 million euro loan agreement for financing the construction of Nameja Rezidence project | - |
| 16.03.2023 | Hepsor Phoenix 2 OÜ, Hepsor AS group company, signed 17.5 million euro loan agreement for financing the construction of Manufaktuuri 7 project | - |
| 13.01.2023 | Hepsor N57 OÜ, Hepsor AS group company, signed 3.1 million euro loan agreement for financing the construction of Lilleküla Kodud project | - |
| 22.10.2021 | Zhongliang Holdings Group Company Limited Announces Repurchase of November 2021 Notes in an Aggregate Principal Amount of USD 12 Million | Zhongliang Holdings Group Company Limited with reference to announcements dated 25 November 2020 and 30 November 2020 in relation to the 8.875% senior notes due November 2021 in the aggregate principal amount of USD 200 million issued by th... |
| 19.10.2021 | Zhongliang Holdings Group Company Limited Announces Repurchase of November 2021 Notes in an Aggregate Principal Amount of USD 9.5 Million | Zhongliang Holdings Group Company Limited announced that on 18 October 2021, the Group repurchased the November 2021 Notes in an aggregate principal amount of USD 9.5 million, representing approximately 4.75% of the aggregate principal amou... |
| 24.09.2020 | ImmVira Group Company Raises US$10M in Strategic Series B Plus Financing | ImmVira Group Company, a Chinese biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics, signed US$10m Series B Plus strategic financing.
This round of financing will be exclusi... |